Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 33,151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Influenza
Interventions: Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo; Drug · Other
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Stroke, Aphasia
Interventions: continuous Theta Burst Stimulation, intermittent Theta Burst Stimulation, Transcranial Magnetic Stimulation Sham, Semantic Feature Analysis; Device · Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: TMJ, TMJ Pain, TMD
Interventions: Erchonia® EVRL™, Placebo Device; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 22 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Acton, Massachusetts

Conditions: Diabetes Prevention
Interventions: Dose 1, Dose 2, Dose 0, Dose 3, Dose 4, Dose 5, Dose 6; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Group B Streptococcus Infections
Interventions: Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more

Conditions: Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions: 25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 89 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Myasthenia Gravis
Interventions: DAS-001; Drug
Lead sponsor: DAS-MG, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ileostomy - Stoma
Interventions: Teduglutide, Placebo; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Lasmiditan, Placebo, Topiramate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Colitis, Ulcerative
Interventions: Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: Spasmodic Torticollis
Interventions: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin, Physiologic saline; Drug · Other
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Generalized Anxiety Disorder
Interventions: RE104 for Injection, Placebo; Drug
Lead sponsor: Reunion Neuroscience Inc; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273.214, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Months to 6 Months
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 39
States / cities: Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more

Conditions: Hot Flashes
Interventions: Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays, Placebo transdermal two 90 μL sprays, Placebo transdermal three 90 μL sprays, Placebo transdermal one 90 μL spray; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 43
States / cities: Birmingham, Alabama • Mobile, Alabama • Oro Valley, Arizona + 37 more

Conditions: Overactive Bladder
Interventions: hMaxi-K, Placebo; Drug · Other
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Branford, Connecticut

Conditions: Anthocyanins
Interventions: ACRB, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Influenza
Interventions: Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more

Conditions: Covid19
Interventions: Tempol, Placebo; Drug · Other
Lead sponsor: Adamis Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Anniston, Alabama • Los Angeles, California • Doral, Florida + 13 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: CBSST + Oxytocin, CBSST + Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: San Diego, California • Baltimore, Maryland

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: methylphenidate, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1986 – 1994
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain
Interventions: Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Dermatitis, Atopic
Interventions: Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS); Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Obesity
Interventions: Walnut shake, Placebo shake; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Recovery From Post-Stroke Aphasia With rTMS Targeting Left or Right Anterior Temporal Lobe

Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

H5N1 Mix and Match With MF59

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Oxytocin and CBSST for People With Schizophrenia

Further Studies of Attention Deficit Disorder - Residual Type (RT)

Radicle Relief 24_RLN: A Study Assessing the Impact of Health and Wellness Products on Pain and Related Health Outcomes.

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

Activation of Brain Centers by Short-term Walnut Consumption in Obesity